Accounts Receivable

12 Months Ended

Dec. 31, 2022

Receivables [Abstract]

Accounts Receivable

Accounts Receivable

The Company’s accounts receivable consists primarily of amounts due from third-party payors and patients. See Note 2 for a summary of the Company’s policies relating to accounts receivable.

Accounts Receivable as of December 31, 2022 and December 31, 2021 consist of the following:

(in thousands)	December 31, 2022		December 31, 2021
Oral drug accounts receivable	$	4,165	$	2,097
Capitated accounts receivable	1,623		665
FFS accounts receivable	26,313		12,530
Clinical trials accounts receivable	2,443		1,823
Other trade receivables	5,272		2,892
Total	$	39,816	$	20,007

During the years ended December 31, 2022 and 2021, the Company had net bad debt recoveries of $169, and bad debt recoveries of $465, respectively, and bad debt expense of $307 and $48, respectively. Bad debt write-offs were a result of accounts receivable on completed contracts that were deemed uncollectible during the period due to delayed collection efforts.